On May 21,2021,a local case of coronavirus disease 2019(COVID-19)was confirmed in a 75-year-old woman(experienced onset of symptoms on May 18)in Liwan District,Guangzhou City,Guangdong Province,China.The number of inf...On May 21,2021,a local case of coronavirus disease 2019(COVID-19)was confirmed in a 75-year-old woman(experienced onset of symptoms on May 18)in Liwan District,Guangzhou City,Guangdong Province,China.The number of infections has increased in the following 10 days and led to 5 generations of transmission.展开更多
Currently,people all over the world have been affected by coronavirus disease 2019(COVID-19).Fighting against COVID-19 is the top priority for all the countries and nations.The development of a safe and effective COVI...Currently,people all over the world have been affected by coronavirus disease 2019(COVID-19).Fighting against COVID-19 is the top priority for all the countries and nations.The development of a safe and effective COVID-19 vaccine is considered the optimal way of ending the pandemic.Three hundred and 44 vaccines were in development,with 149 undergoing clinical research and 35 authorized for emergency use as to March 15 of 2022.Many studies have shown the effective role of COVID-19 vaccines in preventing SARS-CoV-2 infections as well as serious and fatal COVID-19 cases.However,tough challenges have arisen regarding COVID-19 vaccines,including long-term immunity,emerging COVID-19 variants,and vaccine inequalities.A systematic review was performed of recent COVID-19 vaccine studies,with a focus on vaccine type,efficacy and effectiveness,and protection against SARS-CoV-2 variants,breakthrough infections,safety,deployment and vaccine strategies used in the real-world.Ultimately,there is a need to establish a unified evaluation standard of vaccine effectiveness,monitor vaccine safety and effectiveness,along with the virological characteristics of SARS-CoV-2 variants;and determine the most useful booster schedule.These aspects must be coordinated to ensure timely responses to beneficial or detrimental situations.In the future,global efforts should be directed toward effective and immediate vaccine allocations,improving vaccine coverage,SARS-CoV-2 new variants tracking,and vaccine booster development.展开更多
基金The Key-Area Research and Development Program of Guangdong Province(2019B111103001,2020B111107001)The National Natural Science Foundation of China(No.82041030).
文摘On May 21,2021,a local case of coronavirus disease 2019(COVID-19)was confirmed in a 75-year-old woman(experienced onset of symptoms on May 18)in Liwan District,Guangzhou City,Guangdong Province,China.The number of infections has increased in the following 10 days and led to 5 generations of transmission.
基金This study was done according to the principles and guidelines of the Declaration of Helsinki,and was approved by the Research Ethics Committee of the Zhejiang Provincial Center for Disease Control and Prevention(Grant No.2020-24).
文摘Currently,people all over the world have been affected by coronavirus disease 2019(COVID-19).Fighting against COVID-19 is the top priority for all the countries and nations.The development of a safe and effective COVID-19 vaccine is considered the optimal way of ending the pandemic.Three hundred and 44 vaccines were in development,with 149 undergoing clinical research and 35 authorized for emergency use as to March 15 of 2022.Many studies have shown the effective role of COVID-19 vaccines in preventing SARS-CoV-2 infections as well as serious and fatal COVID-19 cases.However,tough challenges have arisen regarding COVID-19 vaccines,including long-term immunity,emerging COVID-19 variants,and vaccine inequalities.A systematic review was performed of recent COVID-19 vaccine studies,with a focus on vaccine type,efficacy and effectiveness,and protection against SARS-CoV-2 variants,breakthrough infections,safety,deployment and vaccine strategies used in the real-world.Ultimately,there is a need to establish a unified evaluation standard of vaccine effectiveness,monitor vaccine safety and effectiveness,along with the virological characteristics of SARS-CoV-2 variants;and determine the most useful booster schedule.These aspects must be coordinated to ensure timely responses to beneficial or detrimental situations.In the future,global efforts should be directed toward effective and immediate vaccine allocations,improving vaccine coverage,SARS-CoV-2 new variants tracking,and vaccine booster development.
